Bleeding and Clotting Disorders Institute

Peoria, Illinois 61664

4 studies enrolling now · 22 studies all time

What they study most

Acquired Hemophilia A, Bleeding Disorder, Congenital Antithrombin Deficiency, Connective Tissue Disorder, Factor IX Deficiency, Factor VIII Deficiency, Hematologic Disorder, Hemophilia, Hemophilia A, Hemophilia A and B, Hemophilia B, Immune Thrombocytopenia (ITP)

Studies at this site

• ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders — Recruiting now
• A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia — Recruiting now
• Efficacy of Atenativ in Patients With Congenital Antithrombin Deficiency Undergoing Surgery or Delivery — Recruiting now
• A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD) — Recruiting now
• ATHN 9: Severe VWD Natural History Study — Completed
• A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) — Completed
• Goal Attainment and Physical Activity in People With Hemophilia A — Stopped early
• Emicizumab in Patients With Acquired Hemophilia A — Running, not enrolling
• A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia — Completed
• Apixaban for the Acute Treatment of Venous Thromboembolism in Children — Completed
• ATHN 11: Liver Transplantation Outcomes Study — Completed
• Assessing Physician and Hemophilia A Patient Reasons and Expectations for Switching Treatment to Kovaltry & Jivi: A Nested Study Within an Existing Registry — Stopped early
• Investigating a Von Willebrand Factor (VWF) Functional Screening Assay for Assigning the Phenotypic Variants of Von Willebrand Disease (VWD) — Completed
• ATHN 2: Factor Switching Study — Completed
• BAX 802 in CHA With Inhibitors — Stopped early
• rVWF IN PROPHYLAXIS — Completed
• Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A — Completed
• BAX 855 Continuation — Completed
• Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures — Completed
• Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) — Completed
• GAS-Hem Feasibility Study — Completed
• Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS — Completed